NCT00844883 - Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Hepatocellular CarcinomaHepatoma

Interventions

DRUG

sorafenib

sorafenib: given 400 mg twice per day for as long as it is beneficial

PROCEDURE

LC Bead-TACE

"LC Beads loaded with doxorubicin~Doxorubicin loaded LC Beads: given intra-arterially into the liver, up to fours times in a 6 month period"

Trial Locations (1)

The Johns Hopkins Hospital, Baltimore